Endologix to Participate in Two Investor Conferences in February

IRVINE, Calif., Feb. 19, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, Chief Executive Officer, and Vaseem Mahboob, Chief Financial Officer, are scheduled to participate at two investor conferences in February. The first conference is the RBC Capital Markets 2016 Global Healthcare Conference in New York City.

The second conference is the 2016 BTIG MedTech Conference in Snowbird, Utah. This conference will allow institutional investors to meet with the Company but does not include a formal presentation.

An audio webcast of the Company’s presentation at the RBC Capital Markets 2016 Global Healthcare Conference will be available by visiting the investor relations section of Endologix’s website at www.endologix.com. A replay of the presentation will be available for 30 days.

About Endologix, Inc.

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company’s focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the U.S. Additional information can be found on Endologix’s website at www.endologix.com. The Nellix System is an investigational device in the United States.

COMPANY CONTACT:

Endologix, Inc.

John McDermott, CEO
Vaseem Mahboob, CFO
(949) 595-7200

www.endologix.com

INVESTOR CONTACTS:

The Ruth Group
Nick Laudico (646) 536-7030
Zack Kubow (646) 536-7020
Source: Endologix

News Provided by Acquire Media